The high efficiency of the CRISPR-Cas9 system has resulted in enhanced recognition of gene editing technology and has resulted in significant investments within the field. Further, the wide application of gene-editing across segments like drug development, agriculture, diagnostics, clinical therapy, and others boost its development.
Given the industry’s solid prospects, investors could consider fundamentally solid gene-editing stocks Eli Lilly and Company (LLY), Sanofi (SNY), and Vertex Pharmaceuticals Incorporated (VRTX) for future health advances.
